We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers
News

University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers

University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers
News

University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery (Horizon) has entered into a research collaboration with the University of Liverpool to identify and validate novel cancer targets and biomarkers for personalized cancer therapy and diagnostics.

Horizon is continuing the process of enabling key academic investigators with its panel of over 150 proprietary genetically-defined isogenic human disease models, with the aim of accelerating the search for new patient-focused drug targets and theranostic biomarkers that could deliver effective ‘personalized’ medicines.

Professor Michael Clague at the University of Liverpool is a world leader the study of a novel class of cancer targets called deubiquitinases that regulate protein stability. Additionally he has established a proteomics platform that allows “global” characterization of molecular signatures within cancer cells.

Horizon’s panels of X-MAN™ (Mutant And Normal) cell-lines represent the first accurate and genetically-defined in vitro models of specific cancer patient populations; and Professor Clague will mine these cellular disease models for unique protein-biomarker signatures. The objectives of the research program are to identify and validate biomarkers that can aid existing drug discovery programmes and to determine whether deubiquitanses represent novel targets in patient populations harboring known cancer mutations such as K-Ras, PI3K, PTEN and EGFR.

Professor Michael Clague says “We are delighted to enter into collaboration with Horizon. As soon as I became aware of the cell lines they had created, it was obvious that they would greatly facilitate our research programme. I am pleased it has been so straightforward to establish a great relationship with the company.”

Commercial details of the transaction remain confidential with the work program beginning in November 2009.
Advertisement